Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance

Bin Xiong, Tao-Jiao Sun, Wei-Dong Hu, Fu-Lin Cheng, Min Mao, Yun-Feng Zhou

Bin Xiong, Tao-Jiao Sun, Wei-Dong Hu, Fu-Lin Cheng, Min Mao, Yun-Feng Zhou, Department of Oncology, Affiliated Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China. Correspondence to: Dr. Yun-Feng Zhou, Affiliated Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China. binxiong88@yahoo.com

Supported by Hubei Province Natural Science Foundation, No. 2000J054

RESULTS: Among 128 cases of colorectal cancer, 87 (67.9%) were positive for cyclooxygenase-2. The expression of cyclooxygenase-2 was significantly correlated with the depth of invasion, stage of disease, and metastasis (lymph node and liver). Patients in T3-T4, stages III-IV and with metastasis had much higher expression of cyclooxygenase-2 than ones in T1-T2, stages I-II and without metastasis (P<0.05). Among 45 cases of colorectal cancer with lymph node metastasis, the COX-2-positive rate was 86.7% (39/45) for primary lesions and diffuse cytoplasmic staining for COX-2 protein was detected in cancer cells in 100% of metastatic lesions of the lymph nodes. VEGF expression was detected in 49 tumors (38.3%), and VEGF expression was closely correlated with COX-2 expression. The positive expression rate of VEGF (81.6%) in the cyclooxygenase-2-positive group was higher than that in the cyclooxygenase-2-negative group (18.4%, P<0.05). MMP-2 expression was detected in 88 tumors (68.8%), and MMP-2 expression was closely correlated with COX-2 expression. The positive expression rate of MMP-2 (79.6%) in the positive COX-2 group was higher than that in the negative COX-2 group (20.4%, P<0.05).

CONCLUSION: Cyclooxygenase-2 may be associated with tumor progression by modulating the angiogenesis and cancer cell motility and invasive potential in colorectal cancer and it can be used as a possible biomarker.
determine the clinical significance of COX-2 in advance of colorectal cancer.

MATERIALS AND METHODS

Patients
A total of 128 cases of colorectal adenocarcinoma that had undergone surgical resection were collected in the Affiliated Zhongnan Hospital of Wuhan University (Wuhan, China) from January 1999 to September 2002, and COX-2, VEGF and MMP-2 immunohistochemical staining were performed. There were 73 men and 55 women, and their age ranged from 23 to 74 years (mean, 56±11 years). Among 128 patients, 26 were well-differentiated adenocarcinoma, 57 moderately differentiated adenocarcinoma, 57 moderately differentiated adenocarcinoma and 45 poorly differentiated adenocarcinoma. According to Dukes’ staging criteria, 37 cases were stage I, 41 stage II, 39 stage III and 11 stage IV.

Methods

Immunohistochemical staining All the tissue specimens were fixed in 100 mol/L neutral formalin and embedded in paraffin. Five-μm thick sections were dewaxed in xylene and dehydrated in ethanol. Tissue sections were washed three times in 0.05 mol/L PBS, and incubated in endogenous peroxidase blocking solution. Non-specific antibody binding was blocked by pretreatment with PBS containing 5 g/L bovine serum albumin. Sections were then rinsed in PBS and incubated overnight at 4 ℃ with diluted anti-COX-2 (Santa Cruz), anti-VEGF (Bosden, Wuhan, China) and anti-MMP-2 (Santa Cruz) antibodies. The steps were performed using S-P detection kit (Maxin, Fuzhou, China) according to the manufacturer’s instructions. PBS was used as substitutes of antibody for negative control. The sections were examined under light microscope.

Evaluation of the staining Evaluation for COX-2 was performed according to the following scoring system: staining intensity was graded as weak (1), moderate (2), or strong (3), and area of staining positivity as <10% (0) of all cells stained in the cytoplasm, 10-40% (1), 40-70% (2), or ≥70% (3). Total scores for grade and area of three or more was defined as positive expression and less than three as negative. Positive signal for VEGF and MMP-2 was located in the cytoplasm or and cell membrane. Immunoreactivity was graded as follows: +, ≥10% stained tumor cells; and −, <10% stained tumor cells.

Statistical analysis
The difference between each group was analyzed by χ² test. P<0.05 was considered significant.

RESULTS

COX-2 expression in colorectal cancer and clinicopathologic findings
COX-2 was expressed in the cytoplasm of cancer cells (Figure 1A) and the expression in primary tumor was noted in 67.9% (87/128). The correlation between COX-2 expression and the clinicopathologic findings is shown in Table 1. The expression of COX-2 was significantly correlated with depth of invasion, stage of disease and metastasis (lymph node and liver). Patients in T3-T4, stages III-IV and metastasis had much higher COX-2 expression than ones in T1-T2, stages I-II and without metastasis (P<0.05). The expression of COX-2 was not correlated with age, gender and differentiation degree of the tumor (P>0.05).

Table 1 Clinicopathologic characteristics of colorectal cancer with expression of COX-2

| Variable            | n    | COX-2 positive  | COX-2 negative |
|---------------------|------|-----------------|----------------|
|                     | n    | n (%)           | n (%)          |
| Sex                 |      |                 |                |
| Male                | 73   | 50 (68.5)       | 23 (31.5)      |
| Female              | 55   | 37 (67.3)       | 18 (32.7)      |
| Age (yr)            | 54±12|                 | 56±11          |
| Histological differentiation |      |                 |                |
| Well                | 26   | 17 (65.4)       | 9 (34.6)       |
| Moderate            | 57   | 40 (70.2)       | 17 (29.8)      |
| Poor                | 45   | 30 (66.7)       | 15 (33.3)      |
| Depth of invasion   |      |                 |                |
| T1-T2               | 81   | 48 (59.3)       | 33 (40.7)      |
| T3-T4               | 47   | 39 (83.0)       | 8 (17.0)*      |
| Metastasis          |      |                 |                |
| Present             | 50   | 42 (84.0)       | 8 (16.0)       |
| Absent              | 78   | 45 (57.7)       | 33 (42.3)*     |
| Dukes stage         |      |                 |                |
| I                   | 37   | 15 (40.5)       | 22 (59.5)      |
| II                  | 41   | 28 (68.3)       | 13 (31.7)      |
| III+IV              | 50   | 44 (88.0)       | 6 (12.0)*      |
| VEGF expression     |      |                 |                |
| Positive            | 49   | 40 (81.6)       | 9 (18.4)       |
| Negative            | 79   | 47 (59.5)       | 32 (40.5)*     |
| MMP-2 expression    |      |                 |                |
| Positive            | 88   | 70 (79.6)       | 18 (20.4)      |
| Negative            | 40   | 17 (42.5)       | 23 (57.5)*     |

*aP<0.05 vs positive.
**Regression, transformation and progression, as well as in tumor carcinoma, and is believed to play a role in tumor growth and function of many cells, including those with biologically active prostanoids. COX-2 modulates the enzyme that catalyzes the conversion of arachidonic acid to endogenous prostaglandin synthesis through inhibition of COX enzymatic activity. These drugs block COX-2 and activates collagenase levels. This study found that the expression of VEGF and MMP-2 in COX-2-positive group is significantly higher than that in COX-2-negative group.**

**Relationship between COX-2, VEGF and MMP-2 expression**

VEGF was mainly localized in the cytoplasm and cell membrane of the tumor cells (Figure 1B). VEGF expression was detected in 49 tumors (38.3%), and VEGF expression was closely correlated with COX-2 expression (Table 1). The positive expression rate of VEGF (81.6%) in the positive COX-2 group was higher than that in the negative COX-2 group (18.4%, P<0.05).

MMP-2 was mainly localized in the cytoplasm and cell membrane of the tumor cells (Figure 1C). MMP-2 expression was detected in 88 tumors (68.8%), and MMP-2 expression was closely correlated with COX-2 expression (Table 1). The positive expression rate of MMP-2 (79.6%) in the positive COX-2 group was higher than that in the negative COX-2 group (20.4%, P<0.05).

**Relationship of COX-2 expression between primary and lymph node metastatic lesions**

Among 45 cases of colorectal cancer with lymph node metastasis, the COX-2 positive rate was 86.7% (39/45) for primary lesions and 100% for metastatic lesions in the lymph nodes. All cases with no staining in the primary lesion showed COX-2 staining in the metastatic lesion in the lymph nodes (Figures 2A, B).

**DISCUSSION**

Epidemiological and experimental studies have demonstrated the effect of non-steroidal anti-inflammatory drugs in the prevention of human cancers. These drugs block COX-2, a inducible enzyme that catalyzes the conversion of arachidonic acid to biologically active prostanoids. COX-2 modulates the growth and function of many cells, including those with malignant transformation. The over-expression of COX-2 has been reported in tissues from patients with different carcinoma, and is believed to play a role in tumor transformation and progression, as well as in tumor regression. Recent experimental studies showed that COX-2 inhibits cell apoptosis, regulates angiogenesis, and is associated with matrix metalloproteinases (MMP).

COX-2 was over-expressed in approximate 80% of colorectal cancer cases, and may be related to the development of colorectal cancer. However, the precise role of COX-2 in colorectal cancer is not yet fully known. Yamauchi et al. reported that COX-2 expression correlated significantly with histologic type, depth of invasion, histologic stage, and metachronous liver metastasis of colorectal cancer. Multivariate analysis for factors associated with metachronous liver metastasis of colorectal cancer showed that COX-2 expression was one of the independent risk factors, second only to lymph node metastasis. COX-2 expression in the primary lesion may be a useful marker for evaluating prognosis and liver metastasis in patients with colorectal cancer. In our study, COX-2 expression was detected in 87 tumors (67.9%). The expression of COX-2 was significantly correlated with the depth of invasion, stage of disease and metastasis (lymph node and liver). Patients in T3-T4, stages III-IV and with metastasis had much higher expression of COX-2 than ones in T1-T2, stages I-II and without metastasis (P<0.05). Among 45 cases of colorectal cancer with lymph node metastasis, the COX-2-positive rate was 86.7% (39/45) for primary lesions and diffuse cytoplasmic staining for COX-2 protein was detected in cancer cells in 100% of metastatic lesions in the lymph nodes. The preferential expression of COX-2 in lymph node metastases suggests a clonal selection of tumor cells with COX-2 expression, specific for the higher potential of lymph node metastasis in tumor advance, and COX-2 plays a role related to the malignant progression of colorectal cancer.

Masferrer et al. reported that COX-2 stimulates endothelial cell migration and vessel tube formation, which are inhibited by NSAIDs. They also reported that COX-2 affects MMP-2 and activated collagenase levels. This study found that the expression of VEGF and MMP-2 in COX-2-positive group is significantly higher than that in COX-2-negative group. The expression of COX-2 is significantly correlated with the expression of VEGF. It demonstrated that COX-2 might be indirectly correlated with angiogenesis through an up-regulation of the expression of VEGF. The expression of COX-2 is also significantly correlated with MMP-2 in colorectal cancer. It indicates that COX-2 can also lead to alterations in the invasive potential of colorectal cancer cells through an up-regulation of the expression of MMP-2. It suggests that COX-2 is closely related to the invasion and metastasis of colorectal cancer and it may be used as a possible biomarker.
REFERENCES

1. Yamauchi T, Watanabe M, Kubota T, Hasegawa H, Ishii Y, Endo T, Kabesima Y, Morozuka K, Yamamoto K, Mukai M. Patients with colorectal cancer. Diet Colon Rectum 2002; 45: 98–103

2. Qiu DK, Ma X, Peng YS, Chen XY. Significance of cyclooxygenase-2 expression in human primary hepatocellular carcinoma. World J Gastroenterol 2002; 8: 815–817

3. Wu QM, Li SW, Wang Q, Wang DH, Li XB, Liu CQ. The expression of COX-2 in esophageal carcinoma and its relation to clinicopathologic characteristics. Shijie Huan Sui Xiaozhao Zhi 2001; 9: 11–14

4. Wu HP, Wu KC, Li L, Yao LP, Lan M, Wang X, Fan DM. Cloning of human cyclooxygenase-2 (COX-2) encoding gene and study of gastric cancer cell transfected with its antisense vector. Shijie Huan Sui Xiaozhao Zhi 2000; 8: 1211–1217

5. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002; 190: 279–286

6. Koki AT, Masferrer JL. Colecis: a specific COX-2 inhibitor with anticancer properties. Cancer Control 2002; 9: 28–35

7. Kakuchi Y, Tsuij S, Tsujii M, Murata H, Kawai N, Yasumaru M, Kimura A, Komori M, Irie T, Miyoshi E, Sasaki Y, Hayashi N, Kawano S, Hiro M. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colonic cancer cells and enhanced liver metastasis. Cancer Res 2002; 62: 1567–1572

8. Hida T, Kishimoto T, Miyashita O, Tatematsu M, Suzuki T, Matsuo K, Sugiyama T, Oga T, Takahashi T, Takahashi T. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase-2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res 2002; 8: 2443–2447

9. Yamada H, Kuroda E, Matsutomo S, Matsumoto T, Yamada T, Yamashita U. Prostaglandin E2 down-regulates viable Bacille Calmette-Guerin-induced macrophage cytotoxicity against murine bladder cancer cell MBT-2 in vitro. Clin Exp Immunol 2002; 128: 52–58

10. Harizi H, Juzan M, Pitard V, Moreau JF, Gualde N. COX-2 inhibitors control metastatic disease in a murine model, Fulton AM. Selective cyclooxygenase (COX)-1 or -2 inhibits inducible macrophage production of endogenous IL-10, which down-regulates den-...

11. Reddy BS, McEntee MF, Jull B, Shi H, Zemel MB, Ornberg RL, Wang Y, Zweifel BS, Koki AT, yuan BS, Chen XY. Significance of COX-2 expression in esophageal carcinoma and its relation to cancer cell viability and study of gastric cancer cell transfected with its antisense vector. Cancer Control 2000; 7: 28–35

12. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression as a new marker for tumor cell migration, invasiveness and angiogenesis. Cancer Control 2000; 7: 20809–20812

13. Dempke W, Sie K, Grothey A, Schmoll HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2001; 127: 411–417

14. Gleryo DW, Saunders MA, Wu KK. COX-2 expression and cell cycle progression in human fibroblasts. Am J Physiol Cell Physiol 2001; 281: C188–C194

15. Chen WS, Wei SJ, Liu JM, Hsiang M, Kou-Lin J, Yang WK. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 2001; 91: 894–899

16. Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 2001; 93: 497–506

17. Williams CS, Tsuji M, Reese J, Dey Sk, DuBois RN. Host cyclooxygenase-2 promotes colorectal cancer growth. J Clin Invest 2000; 105: 1589–1594

18. Marrogi A, Pass HL, Khan M, Metheny-Barlow J, Harris CC, Cerwin BI. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2); in vivo antiproliferative effects of a COX-2 inhibitor. Cancer Res 2000; 60: 3696–3700

19. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000; 6: 135–138

20. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Paterno SR. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000; 60: 4629–4637

21. Shao J, Sheng H, Inoue H, Morrow JD, DuBois RN. Regulation of constitutive cyclooxygenase-2 expression in colon cancer cells. J Biol Chem 2001; 275: 33951–33956

22. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306–1311

23. Reddy BS, Hirose Y, Lutet R, Steele V, Kelloff G, Paulson S, Seibert K, Rao CV. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000; 60: 293–297

24. Hsu CT, Chiu CF, Kelsen DP, Schwartz GK. Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis. Cancer Chemother Pharmacol 2000; 45: 389–396

25. Hida T, Kozaki K, Moramtsu H, Masuda A, Shimizu S, Mitsudomi T, Sugiyama T, Oga T, Takahashi T, Takahashi T. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000; 6: 2006–2011

26. Hull MA, Fenwick SW, Chapple KS, Scott N, Tooogood GJ, Lodge JP. Cyclooxygenase-2 expression in colorectal cancer liver metastases. Clin Exp Metastasis 2000; 18: 21–27

27. Ferrario A, Von Tiehl K, Wong S, Luna M, Gomez CJ. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res 2002; 62: 3956–3961